Bracco Gains EU Approval to Expand Contrast Agent Use in Infants
Event summary
- The European Commission extended the Marketing Authorisation for Bracco’s Vueway® (gadopiclenol) to include pediatric patients under 2 years of age, effective January 23, 2026.
- This approval followed a positive opinion from the CHMP and a recommendation from the EMA.
- Vueway® is approved in 36 countries and used for MRI contrast enhancement.
- Clinical studies indicate Vueway® delivers comparable diagnostic efficacy at half the gadolinium dose of gadobutrol.
- Bracco and Guerbet have a collaboration for Gadopiclenol manufacturing and R&D, with both companies expected to manufacture the active ingredient and finished product after a transition period.
The big picture
This approval represents a strategic win for Bracco, expanding the addressable market for Vueway® and reinforcing its position as a leader in advanced diagnostic imaging. The move to lower-dose imaging reflects growing concerns about gadolinium retention and its potential long-term health effects, a trend likely to shape future regulatory decisions and product development in the contrast agent market. The collaboration with Guerbet, while complex, positions both companies to capitalize on the growing demand for innovative imaging solutions.
What we're watching
- Adoption Rate
- The speed of adoption among pediatric radiologists and the impact on overall Vueway® sales will be key indicators of the approval’s success.
- Liability Risk
- The long-term safety profile of gadolinium exposure in neonates will be closely scrutinized, potentially leading to further regulatory action or litigation.
- Competitive Response
- Guerbet and other contrast agent manufacturers will likely accelerate their own R&D efforts to compete with Vueway®’s expanded indication and lower dosage.
Related topics